Full-Time

Key Account Manager

Cardiovascular

Posted on 4/15/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$163.2k - $194.6k/yr

+ Bonus + Sales-based Incentive Plan

Mid, Senior

Indianapolis, IN, USA

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Requirements
  • Doctorate degree & 2 years of sales experience and/or related account management experience
  • Master’s degree & 4 years of sales experience and/or related account management experience
  • Bachelor’s degree & 6 years of sales experience and/or related account management experience
Responsibilities
  • Assess and diagnose the current business environment in assigned accounts
  • Develops and executes innovative strategies to reach difficult to access health care providers and accounts in a compliant manner
  • Maintains comprehensive account profile / needs assessment / strategic plan
  • Responsible for routinely meeting with appropriate opinion leaders in Cardiology, Lipidology, Pharmacy, P&T Committee, etc.
  • Presents MAC approved data and CV product messaging for approved CV products
  • Accountable for ensuring formulary adoption in targeted / assigned hospital accounts
  • Monitors Amgen business performance across Cardiovascular portfolio
  • Identifies drivers/barriers and coordinates pull-through initiatives across field teams
  • Coordinates Amgen home office engagement with customers
  • Builds and develops professional relationships with key customer decision-makers
  • Partners closely with Organized Customer Team Regional Account Executives and Regional Medical Liaisons
  • Coordinates with Reimbursement Access Value team to support open access to Amgen portfolio
  • Provides actionable field intelligence and recommendations to Amgen home office
  • Leads contract delivery, business reviews and performance tracking
  • Organizes competitive response
  • Shapes the environment
  • Executes value/FDAMA 114 tools where appropriate
Desired Qualifications
  • 3+ years of account management and/or public payor experience strongly preferred
  • Advanced degree (e.g. MPH, MBA, PharmD, etc.) 7+ years of healthcare sales and/or marketing experience
  • Clinic, hospital, dyslipidemia, heart failure, access environment, applicable competitors, and industry experience preferred
  • Cardiology experience, including dyslipidemia, heart failure and acute coronary syndromes, highly preferred
  • District Management Experience preferred
  • Reimbursement / managed care experience highly desirable
  • Experience in public payor / agency activities, including understanding of the Local Coverage Determination Processes (LCD) strongly preferred
  • Knowledge of hospital committee structure, P&T process, treatment and discharge protocols, DRG and hospital reimbursement process
  • Functional knowledge of Medicare and Government agencies
  • Knowledge of payor systems, billing, coding and reimbursement processes
  • Knowledge of CMS policies and processes

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.